ziritaxestat

Ziritaxestat is an investigational small molecule drug that acts as a selective inhibitor of autotaxin (ENPP2 protein), the main enzyme responsible for lysophosphatidic acid (LPA) production. LPA is a pro-fibrotic and pro-inflammatory lipid mediator implicated in diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc). By inhibiting autotaxin, ziritaxestat reduces LPA levels, aiming to mitigate fibrotic processes. The drug was co-developed by Galapagos and Gilead Sciences. It reached phase 3 clinical trials for IPF but failed to demonstrate efficacy in these studies; development has been discontinued for all indications[4][5][6][7].

Other names

ziritaxestat2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrileziritaxestatum